Arca
Skip to content
Tools
Tools

CYP17A1: Steroid 17-alpha-hydroxylase/17,20 lyase

A cytochrome P450 monooxygenase involved in corticoid and androgen biosynthesis.

  • Drugs that act on it: 6
  • Approved: 3
  • In phases 1 to 3: 3
  • Sponsors: 5

Who is on it, and how far along

Every drug ChEMBL records acting on CYP17A1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 6

Approved3

  • Abiraterone
  • Abiraterone acetate
  • Levoketoconazole

Phase 32

  • Galeterone
  • Orteronel

Phase 21

  • Seviteronel

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • Innocrin Pharmaceutical117%
    • Ltn Pharmaceuticals, Inc.117%

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Cytochrome P450 17A1 inhibitor.
    AbirateroneApprovedJohnson & JohnsonSmall moleculeInhibitor173
    Abiraterone acetateApprovedJohnson & JohnsonSmall moleculeInhibitor107
    LevoketoconazoleBoxed warningApprovedStrongbridgeSmall moleculeInhibitor0
    GaleteronePhase 3Ltn Pharmaceuticals, Inc.Small moleculeInhibitor1
    OrteronelPhase 3Takeda Pharmaceuticals USASmall moleculeInhibitor0
    SeviteronelPhase 2Innocrin PharmaceuticalSmall moleculeInhibitor1

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 15 in all, from ClinicalTrials.gov.
    MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A)Abiraterone, Abiraterone acetatePhase 1 / Phase 2Not yet recruitingMerck Sharp & Dohme LLCNov 2, 2026
    Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate CancerAbiraterone, Abiraterone acetatePhase 2 / Phase 3Not yet recruitingECOG-ACRIN Cancer Research GroupOct 1, 2026
    A Study Testing if Patients With Advanced Prostate Cancer Who Are Responding Well to Combination Treatment Can Safely Reduce Their Medication to a Single Hormone Therapy, Compared to Continuing Their Current DrugsAbirateronePhase 2Not yet recruitingKokilaben Dhirubhai Ambani Hospital and Medical Research InstituteSep 24, 2026
    Abiraterone With Dalpiciclib in Salivary Gland CarcinomaAbirateronePhase 2RecruitingShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversitySep 11, 2026
    A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]AbirateronePhase 3RecruitingGlaxoSmithKlineSep 3, 2026
    A Prospective Study Based on Spatial Multi-omics to Predict the Efficacy of ADT Combined With Second-generation Novel Hormonal Agents in Metastatic Hormone-sensitive Prostate Cancer.AbirateronePhase 2Not yet recruitingAnhui Medical UniversityAug 31, 2026
    Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate CancerAbirateronePhase 3RecruitingUniversity College, LondonAug 7, 2026
    Study of XNW5004 Tablets in Advanced Prostate CancerAbiraterone, Abiraterone acetatePhase 2Not yet recruitingEvopoint Biosciences Inc.Jul 28, 2026
    Observing the Real-world Non-interventional Study of Abiraterone Acetate Tablets (II) in Treating Chinese Patients With Metastatic Prostate CancerAbiraterone acetate—Active, not recruitingThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolJul 23, 2026
    A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)Abiraterone acetatePhase 3RecruitingORIC PharmaceuticalsJul 23, 2026
    Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Prostate Cancer Patients.Abiraterone acetatePhase 2RecruitingInstituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología RadioterápicJul 21, 2026
    Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE TrialAbiraterone acetatePhase 2RecruitingMayo ClinicJun 16, 2026
    AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)Abiraterone acetatePhase 3RecruitingAstraZenecaMay 28, 2026
    Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast CancerSeviteronelPhase 1 / Phase 2RecruitingSt Vincent's Hospital, SydneyJul 1, 2021
    1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic AdenocarcinomaGaleteronePhase 2Active, not recruitingUniversity of Maryland, BaltimoreSep 20, 2019

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations
    • Congenital adrenal hyperplasia due to 17-alpha-hydroxylase deficiency0.80
    • 17,20-lyase deficiency, isolated0.73
    • Adrenal gland disorder0.59
    • 17-alpha-hydroxylase/17,20-lyase deficiency, combined complete0.53
    • Prostate neoplasm0.53
    • 17-alpha-hydroxylase/17,20-lyase deficiency, combined partial0.52
    • Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency0.43
    • Prostate carcinoma0.41
    • Neoplasm0.39

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3522, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-20. Gene name, function (UniProt P05093, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.